285 related articles for article (PubMed ID: 16298986)
1. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
[TBL] [Abstract][Full Text] [Related]
2. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
3. Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
König RR; Flory E; Steidl S; Neumann J; Coulibaly C; Holznagel E; Holzammer S; Norley S; Cichutek K
J Virol; 2002 Nov; 76(21):10627-36. PubMed ID: 12368305
[TBL] [Abstract][Full Text] [Related]
4. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
Polzer S; Dittmar MT; Schmitz H; Schreiber M
Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
[TBL] [Abstract][Full Text] [Related]
5. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Nabatov AA; Pollakis G; Linnemann T; Kliphius A; Chalaby MI; Paxton WA
J Virol; 2004 Jan; 78(1):524-30. PubMed ID: 14671134
[TBL] [Abstract][Full Text] [Related]
6. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
7. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
8. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
9. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
[TBL] [Abstract][Full Text] [Related]
10. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
11. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
12. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
Gorry PR; Dunfee RL; Mefford ME; Kunstman K; Morgan T; Moore JP; Mascola JR; Agopian K; Holm GH; Mehle A; Taylor J; Farzan M; Wang H; Ellery P; Willey SJ; Clapham PR; Wolinsky SM; Crowe SM; Gabuzda D
Virology; 2007 May; 362(1):163-78. PubMed ID: 17239419
[TBL] [Abstract][Full Text] [Related]
13. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
Jensen MA; Li FS; van 't Wout AB; Nickle DC; Shriner D; He HX; McLaughlin S; Shankarappa R; Margolick JB; Mullins JI
J Virol; 2003 Dec; 77(24):13376-88. PubMed ID: 14645592
[TBL] [Abstract][Full Text] [Related]
14. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
[TBL] [Abstract][Full Text] [Related]
15. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
[TBL] [Abstract][Full Text] [Related]
16. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Envelope Surface Glycoprotein from HIV-2 Primary Isolates with Different Coreceptor Usage Profile.
Cerejo P; Santos-Costa Q; Calado M; Espírito-Santo M; Parreira R; Azevedo-Pereira JM
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):218-221. PubMed ID: 29258330
[TBL] [Abstract][Full Text] [Related]
18. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.
Li Y; Rey-Cuille MA; Hu SL
AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1473-9. PubMed ID: 11709091
[TBL] [Abstract][Full Text] [Related]
19. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.
Cashin K; Jakobsen MR; Sterjovski J; Roche M; Ellett A; Flynn JK; Borm K; Gouillou M; Churchill MJ; Gorry PR
Retrovirology; 2013 Sep; 10():98. PubMed ID: 24041034
[TBL] [Abstract][Full Text] [Related]
20. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
